Added to YB: 2025-11-12
Pitch date: 2025-11-05
GRFS [neutral]
Grifols, S.A.
-11.61%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
Market Cap
EUR 5.4B
Pitch Price
EUR 10.74
Price Target
N/A
Dividend
3.45%
EV/EBITDA
9.52
P/E
14.27
EV/Sales
2.25
Sector
Biotechnology
Category
turnaround
Medtech, telcos and AI fears - Grifols (GRFS)
GRFS (quick overview): Q3 showed operational progress with strong immunoglobulin performance but weak albumin/China pricing. EBITDA above consensus yet FCF remains anemic. Leverage stuck >5x EBITDA despite improved cash flow. 2027 debt maturity cliff unaddressed. Mgmt prioritizes dividends over deleveraging. Recovery remains cosmetic amid execution risk.
Read full article (2 min)